Healthcare

Poll: Most voters think COVID-19 likely came from Chinese lab

Published

2 years ago

May 27, 2021

According to the most recent Rasmussen poll, most likely American voters agree that the origin of the COVID-19 virus is suspicious enough that it should be investigated. A majority also suspects it came straight from a Chinese laboratory.

53% of respondents believe it is “very important” for authorities to investigate the virus’s origins. Meanwhile, 29% responded it was “somewhat important” to do so. Ages 65+ had the highest majority that was for an investigation, then the 40-64 age group, then the 18-39 age group. This comes the day after President Biden announced that he “asked the Intelligence Community to redouble their efforts to collect and analyze information that could bring us closer to a definitive conclusion,” according to a statement. Biden demanded a report within 90 days.

Further, 43% believed it was very likely that it originated from a Chinese lab. Reports have claimed that staffers from the Wuhan Virology Instituted came down with COVID-like symptoms as early as November 2019.

See the findings here.

You can follow Jenny Goldsberry on Twitter @jennyjournalism.

Related Topics:poll Rasmussen Wuhan wuhan virology institute

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

2 days ago

June 7, 2023

Sara Carter Staff

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4

— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.